“…However, the availability of large multidisciplinary weight management programs with comprehensive multidisciplinary intervention and tertiary care intervention is limited with large sections of the United States lacking obesity medicine specialists, in particular those with experience with pediatric obesity management. Positive weight loss results have been observed in numerous studies with younger children having a greater reduction in BMI z-score in comparison to adolescents when analyzing the effects of multidisciplinary interventions on weight loss and health outcomes in children and adolescents with severe obesity [10,13]. In other studies, adolescents with the most severe obesity had the greatest reductions in BMI [14].…”
Section: Pediatric Obesity Algorithm and Multidiscplinary Approach To...mentioning
confidence: 91%
“…We have detailed the guidelines and challenges to management of obesity in childhood through the Pediatric Obesity Algorithm, an evidence-based roadmap for the diagnosis and management of children with obesity [9,10]. In the Algorithm, we discuss agespecific recommendations that were developed for use by practicing clinicians with topics ranging from assessment to the diagnosis and treatment of obesity comorbidities [9,11].…”
Section: Pediatric Obesity Algorithm and Multidiscplinary Approach To...mentioning
confidence: 99%
“…with a BMI percentile at the >95th percentile have a greater chance of maintaining obesity into adulthood [10,18].…”
Section: Endocrinology and Metabolismmentioning
confidence: 99%
“…Metformin is commonly utilized in the population of children and adolescents, although FDA approved only in children 10 years with T2DM. However, metformin has been prescribed by obesity medicine specialists for polycystic ovary syndrome or severe insulin resistance with or without impaired glucose tolerance, with multiple trials [19,20] showing a small amount of weight loss associated with metformin use, particularly in the first few months of medication initiation [10]. By age 17 or 18, when more pharmaceutical treatment options are FDA approved, comorbidities have developed.…”
Purpose of reviewIn this review, we discuss new medical and surgical options for the treatment of children and adolescents with obesity. We review the impact of COVID-19 on this vulnerable population. We also discuss the recent availability of screening tests for rare genetic causes of obesity.Recent findingsCOVID-19 increased the prevalence of obesity among children and adolescents. This population is at increased risk for severe disease. The field of pediatric obesity has benefited from the approval of two new antiobesity medications: liraglutide and setmelanotide. We discuss indications for their use. New guidelines for surgical options for the treatment of children and adolescents with obesity are reviewed. These options are increasingly used as part of the comprehensive care for these children.SummaryThe epidemic of childhood obesity continues. COVID-19 and the associated isolation contributed to the problem. However, promising new medical and surgical therapies and screening tests for rare genetic causes of obesity are available. These new diagnostic and therapeutic options bring renewed enthusiasm to the treatment of children and adolescents with obesity and increased recognition that obesity is a chronic disease starting in childhood deserving intervention to prevent consequences.
“…However, the availability of large multidisciplinary weight management programs with comprehensive multidisciplinary intervention and tertiary care intervention is limited with large sections of the United States lacking obesity medicine specialists, in particular those with experience with pediatric obesity management. Positive weight loss results have been observed in numerous studies with younger children having a greater reduction in BMI z-score in comparison to adolescents when analyzing the effects of multidisciplinary interventions on weight loss and health outcomes in children and adolescents with severe obesity [10,13]. In other studies, adolescents with the most severe obesity had the greatest reductions in BMI [14].…”
Section: Pediatric Obesity Algorithm and Multidiscplinary Approach To...mentioning
confidence: 91%
“…We have detailed the guidelines and challenges to management of obesity in childhood through the Pediatric Obesity Algorithm, an evidence-based roadmap for the diagnosis and management of children with obesity [9,10]. In the Algorithm, we discuss agespecific recommendations that were developed for use by practicing clinicians with topics ranging from assessment to the diagnosis and treatment of obesity comorbidities [9,11].…”
Section: Pediatric Obesity Algorithm and Multidiscplinary Approach To...mentioning
confidence: 99%
“…with a BMI percentile at the >95th percentile have a greater chance of maintaining obesity into adulthood [10,18].…”
Section: Endocrinology and Metabolismmentioning
confidence: 99%
“…Metformin is commonly utilized in the population of children and adolescents, although FDA approved only in children 10 years with T2DM. However, metformin has been prescribed by obesity medicine specialists for polycystic ovary syndrome or severe insulin resistance with or without impaired glucose tolerance, with multiple trials [19,20] showing a small amount of weight loss associated with metformin use, particularly in the first few months of medication initiation [10]. By age 17 or 18, when more pharmaceutical treatment options are FDA approved, comorbidities have developed.…”
Purpose of reviewIn this review, we discuss new medical and surgical options for the treatment of children and adolescents with obesity. We review the impact of COVID-19 on this vulnerable population. We also discuss the recent availability of screening tests for rare genetic causes of obesity.Recent findingsCOVID-19 increased the prevalence of obesity among children and adolescents. This population is at increased risk for severe disease. The field of pediatric obesity has benefited from the approval of two new antiobesity medications: liraglutide and setmelanotide. We discuss indications for their use. New guidelines for surgical options for the treatment of children and adolescents with obesity are reviewed. These options are increasingly used as part of the comprehensive care for these children.SummaryThe epidemic of childhood obesity continues. COVID-19 and the associated isolation contributed to the problem. However, promising new medical and surgical therapies and screening tests for rare genetic causes of obesity are available. These new diagnostic and therapeutic options bring renewed enthusiasm to the treatment of children and adolescents with obesity and increased recognition that obesity is a chronic disease starting in childhood deserving intervention to prevent consequences.
“…Prevalence of obesity significantly increased in children aged 2–5 years, adolescents 12–19 years, and all children aged 2–19 years in all races and ethnicities [ 2 ]. Early intervention is crucial and adolescents with body mass index (BMI) > 95th%ile have a higher risk of obesity persisting into adulthood than younger children [ 3 , 4 ].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.